Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?



Allen, John C, Talab, Fatima and Slupsky, Joseph R ORCID: 0000-0002-7410-9004
(2016) Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? International journal of hematologic oncology, 5 (1). 37 - 53.

[img] Text
Targetting BCR signalling in leukaemia and lymphoma version Author approved version.pdf - Accepted Version

Download (995kB)

Abstract

B-lymphocytes are dependent on B-cell receptor (BCR) signaling for the constant maintenance of their physiological function, and in many B-cell malignancies this signaling pathway is prone to aberrant activation. This understanding has led to an ever-increasing interest in the signaling networks activated following ligation of the BCR in both normal and malignant cells, and has been critical in establishing an array of small molecule inhibitors targeting BCR-induced signaling. By dissecting how different malignancies signal through BCR, researchers are contributing to the design of more customized therapeutics which have greater efficacy and lower toxicity than previous therapies. This allows clinicians access to an array of approaches to best treat patients whose malignancies have BCR signaling as a driver of pathogenesis.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 19 Aug 2016 09:17
Last Modified: 16 Sep 2021 23:12
DOI: 10.2217/ijh-2016-0003
URI: https://livrepository.liverpool.ac.uk/id/eprint/3001481